LY6K and cancer: In particular, it has been demonstrated that TTK protein kinase (TTK), up-regulated lung cancer 10 (URLC10) and insulin-like growth factor–II mRNA binding protein 3 (KOC1) are promising targets for cancer vaccination in advanced ESCC patients [22,23].